Polaris Partners — 2016 Investments
8 investments dated 2016 · listed companies and verified rows first · show all
Cartesian Therapeutics is a biotechnology company developing cell therapies, formed through the November 2023 merger with Selecta.
BiotechHealthtechWatertown, US
Metin Kurtoglu(Executive Officer)Chris Jewell(Executive Officer)Carsten Brunn(President, CEO & Chairman of the Board)inEmily English(Executive Officer)Blaine Davis(Executive Officer)Stephen Smolinksi(Executive Officer)
Board seatAmir Nashat· per SEC Form D · $70M raise · filed Jan 2020
Co-investorsK2 HealthVenturesMaryland TEDCOSchooner CapitalTEDCO
Daré Bioscience is a women's health biotech company that conducts end-to-end clinical development of targeted therapeutics and products for conditions across areas such as contraception, menopause, vaginal infections, and sexual wellness.
BiotechDigital HealthFemTechSan Diego, US
MarDee Haring-Layton(Chief Accounting Officer)Sabrina Martucci Johnson(Founder & Chief Executive Officer)Christopher D.T. Guiffre(Executive Officer, Director)Gregg Beloff(Executive Officer)Alejandra V. Carvajal(Executive Officer)Adrian Senderowicz(Executive Officer)
Board seatAlan Crane· per SEC Form D · $1 raise · filed Oct 2016
BiotechBoston, US
Mary DiBiase(Executive Officer)Christophe Arbet-Engels(Executive Officer)David Kirske(Executive Officer)John Volpone(Executive Officer)Mark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)
Board seatAmy SchulmanTerrance McGuire· per SEC Form D · $50.5M raise · filed May 2017
Co-investorsOmega Funds
Bedford, US
Franciscus J.A. van Mierlo(Executive Officer, Director)
BoardReidar Langmo(Director)Robert Metcalfe(Director)Carmichael Roberts(Director)Yasheng Huang(Director)Bruce Sohn(Director)
Board seatAmir Nashat· per SEC Form D · $30M raise · filed May 2016
Watertown, US
Maria Palasis(Director, Executive Officer)
BoardRobert Langer(Director)Guido Neels(Director)Richard Mott(Director)Carmichael S. Roberts(Director)
Board seatTerrance McGuire· per SEC Form D · $6M raise · filed Nov 2016
Phoenix, US
Mark Verstegen(Executive Officer, Director)Dan Burns(Executive Officer, Director)Peter Hotz(Director)Timothy Kilgallon(Director)Rick Smith(Executive Officer)Jonathan Flint(Director)in
Board seatJonathan Flint· per SEC Form D · $193.8K raise · filed Feb 2016
Co-investorsABS Capital Partners
Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.
BiotechDigital HealthHealthtechCambridge, US
PETER M. HECHT(Executive Officer, Director)MARK G. CURRIE(Executive Officer)HALLEY E. GIBLERT(Executive Officer)THOMAS GRANEY(Executive Officer)THOMAS A. MCCOURT(Executive Officer)
Board seatTerrance G. Mcguire· per SEC Form D · $150M raise · filed Oct 2016
Co-investorsF-Prime CapitalMountain Group CapitalRidgeback CapitalVenrockMaverick Ventures
Sofregen develops medical biomaterials based on purified silk protein for soft tissue regeneration, including injectable fillers and applications such as vocal fold medialization.
BiotechHealthtechMedical DevicesCambridge, US
Milan Kofol(Executive Officer)Doug Sheldon(Director)Anh Hoang(Executive Officer)Howard Weisman(Executive Officer, Director)
Board seatAmir Nashat· per SEC Form D · $9.7M raise · filed Sep 2017
Co-investorsAnzu Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.